Models, mechanisms and clinical evidence for cancer dormancy.
about
Biomarkers of residual disease, disseminated tumor cells, and metastases in the MMTV-PyMT breast cancer modelERp29 induces breast cancer cell growth arrest and survival through modulation of activation of p38 and upregulation of ER stress protein p58IPKuPAR promotes formation of the p130Cas-Crk complex to activate Rac through DOCK180.Seeding and propagation of untransformed mouse mammary cells in the lungTargeting microRNAs as key modulators of tumor immune responseTargeting the CCL2-CCR2 signaling axis in cancer metastasisCancer stem cells and immunoresistance: clinical implications and solutionsBioengineering Models for Breast Cancer ResearchCancer Metastases: Early Dissemination and Late RecurrencesSingle-cell analysis tools for drug discovery and developmentCancer Dormancy: A Regulatory Role for Endogenous Immunity in Establishing and Maintaining the Tumor Dormant StateTargeting Breast Cancer MetastasisHead and neck cancer: metronomic chemotherapyEvolutionary determinants of cancerMolecular alterations that drive breast cancer metastasis to boneUnderstanding the Biology of Bone Sarcoma from Early Initiating Events through Late Events in Metastasis and Disease ProgressionDynamic changes in numbers and properties of circulating tumor cells and their potential applicationsIntratumoral heterogeneity: Clonal cooperation in epithelial-to-mesenchymal transition and metastasisMetastatic mechanisms in follicular cell-derived thyroid cancerMinimal residual disease and circulating tumor cells in breast cancerMicroRNA regulation in cancer-associated fibroblastsMetronomic Chemotherapy--A New Path to Treat Advanced Non-small Cell Lung CancerTargeting tumor-stromal interactions in bone metastasisReview of tumor dormancy therapy using traditional oriental herbal medicineMechanisms of disseminated cancer cell dormancy: an awakening fieldNanoparticle induced cell magneto-rotation: monitoring morphology, stress and drug sensitivity of a suspended single cancer cellOsteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche.The growth threshold conjecture: a theoretical framework for understanding T-cell toleranceThe multifaceted roles of autophagy in tumors-implications for breast cancer.Escaping Antiangiogenic Therapy: Strategies Employed by Cancer CellsBlood-based Tumor Markers in Lung CancerTumor cell dormancyTGFβ Signaling in Tumor Initiation, Epithelial-to-Mesenchymal Transition, and MetastasisTumour-derived miRNAs and bone metastasisDelayed systemic recurrence of uveal melanomaTumor-vascular interactions and tumor dormancyCell cycle arrest and cell survival induce reverse trends of cardiolipin remodelingTranscriptional changes induced by the tumor dormancy-associated microRNA-190Cancer evolution and individual susceptibilityIdentification of novel drugs to target dormant micrometastases
P2860
Q21090788-A49334A2-3E8D-4D20-B75E-A135FA82943DQ24296295-529083A0-1063-48CD-8E2B-ABAD99261E9EQ24642555-C1A48570-5B1E-41A5-AEF5-FDF10E9165A1Q24648060-F6D76B48-AF6F-4E56-8F58-A9C56CB1D895Q26746972-439E3E40-A3E6-40AE-9132-5D7D5384F46FQ26765184-5F497800-33FF-447C-9E08-A793A0E950B4Q26769757-3E47CAD1-9828-4E79-B07C-67F646D05598Q26770495-9ABE95C0-D748-4C2B-826D-A19112BFCDB5Q26774164-4773EED2-D4AF-49B3-AA55-5C05F0C22B59Q26775754-12BF436E-D5F6-4339-B0E7-58BB936FEF3EQ26782573-0F128496-861F-4FC2-ABD8-F3CEACA3C080Q26783925-9E9FC64B-48CD-40B5-852A-BEEE16843C03Q26784018-6D45BABA-962C-4659-A656-818AA522ADBDQ26801710-F87B6B7A-419C-4F9F-AD54-A187756C957CQ26829858-9F24606F-C9DB-41F5-B8C2-658DF6A92F79Q26829949-76840996-B98C-4E06-BCBF-3A30DE836E02Q26853569-71356F70-59AD-49D5-A96B-6F3411AEB6ABQ26991480-A90BF6D1-DE6B-4C1F-B104-33E02864B9CFQ27005646-4EF05F32-7AAE-4DF9-91B1-DAC1A22CEEEFQ27010152-5D3D9960-ABA4-4DA1-A3B1-F2385121FD38Q27010255-5B8D7AAA-166C-4170-AD6A-B8BA4918C8F8Q27015786-F4CEAADB-4B2B-4E25-B9C3-38F88D145811Q27024561-E4774BE3-8769-4A83-AD22-B6DCDE25221AQ27025327-8DD84AB3-B9D6-400F-AC50-66E04112FCA3Q27027015-AA041D6A-9CD0-41FD-994E-9691823D1AA5Q27311385-4D38734B-E806-413A-986B-54463D5A62BCQ27316833-A58D3C19-1833-451B-86C6-D1BE4B39015AQ27335659-16E59ED6-7E57-470C-8EEA-E5B33E115FD6Q27692102-DB950F56-01B1-4397-9B40-0D332B102CE6Q28067753-F83F758E-9F42-4F02-B85C-3AF5D55C5807Q28072736-59BBBEF1-1B7A-449E-A4FB-C9CFE5B1DA20Q28073065-52BF88FD-342F-447C-A585-667E3AFA5EE2Q28083107-3C0EE51F-6AE7-4DD9-8CAF-A46E85FB91DAQ28086895-667EC257-684B-422A-96D1-09BCFFE8188BQ28268997-36882154-25D6-425E-BB48-85808D82E3A3Q28295975-6E60A47B-73BA-4588-8C36-E0253A8B33B8Q28383069-6F2CF2CF-8288-46D3-98D6-DC3C71178C46Q28383492-4B7A9F52-0B59-4A17-AD66-D3C5048B6677Q28389946-EBADD99C-EA67-43E2-9CAE-D2B11E890F09Q28394296-320E090F-EDFF-4590-A5C3-1E05715EF85B
P2860
Models, mechanisms and clinical evidence for cancer dormancy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Models, mechanisms and clinical evidence for cancer dormancy.
@en
type
label
Models, mechanisms and clinical evidence for cancer dormancy.
@en
prefLabel
Models, mechanisms and clinical evidence for cancer dormancy.
@en
P2860
P356
P1476
Models, mechanisms and clinical evidence for cancer dormancy.
@en
P2093
Julio A Aguirre-Ghiso
P2860
P2888
P304
P356
10.1038/NRC2256
P407
P577
2007-11-01T00:00:00Z
P5875
P6179
1030922165